GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » Price-to-Owner-Earnings

Boiron (FRA:BON) Price-to-Owner-Earnings : 14.70 (As of May. 21, 2025)


View and export this data going back to . Start your Free Trial

What is Boiron Price-to-Owner-Earnings?

As of today (2025-05-21), Boiron's share price is €24.40. Boiron's Owner Earnings per Share (TTM) ended in Dec. 2024 was €1.66. It's Price-to-Owner-Earnings for today is 14.70.


The historical rank and industry rank for Boiron's Price-to-Owner-Earnings or its related term are showing as below:

FRA:BON' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.02   Med: 11.94   Max: 84.92
Current: 14.82

During the past 13 years, the highest Price-to-Owner-Earnings of Boiron was 84.92. The lowest was 6.02. And the median was 11.94.


FRA:BON's Price-to-Owner-Earnings is ranked better than
70.63% of 446 companies
in the Drug Manufacturers industry
Industry Median: 24.845 vs FRA:BON: 14.82

As of today (2025-05-21), Boiron's share price is €24.40. Boiron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €0.65. Therefore, Boiron's PE Ratio (TTM) for today is 37.54.

As of today (2025-05-21), Boiron's share price is €24.40. Boiron's EPS without NRI for the trailing twelve months (TTM) ended in was €1.64. Therefore, Boiron's PE Ratio without NRI for today is 14.90.

During the past 13 years, Boiron's highest PE Ratio without NRI was 34.97. The lowest was 10.54. And the median was 17.70.


Boiron Price-to-Owner-Earnings Historical Data

The historical data trend for Boiron's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron Price-to-Owner-Earnings Chart

Boiron Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.79 60.17 16.42 12.48 16.08

Boiron Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.42 - 12.48 - 16.08

Competitive Comparison of Boiron's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boiron's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Boiron's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Boiron's Price-to-Owner-Earnings falls into.


;
;

Boiron Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Boiron's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=24.40/1.66
=14.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boiron  (FRA:BON) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Boiron Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Boiron's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Boiron Business Description

Traded in Other Exchanges
Address
2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.